SYTL4 May Serve as a New Predictive Biomarker for Survival and Trastuzumab Treatment Responsiveness in HER2-Positive Breast Cancer
Pawel Kordowitzki · 2026
Read SYTL4 May Serve as a New Predictive Biomarker for Survival and Trastuzumab Treatment Responsiveness in HER2-Positive Breast Cancer by Pawel Kordowitzki (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13206864.txt.
Description
Pawel Kordowitzki, writing alone, presents a 2026 study of a gene called SYTL4 as a possible marker in breast cancer. Breast cancer is the most common cancer in women worldwide. Good markers help doctors pick the right treatment for each patient and avoid needless side effects.
Using public gene data sets, the study found SYTL4 levels lower in tumors with BRCA1 mutations. In HER2-positive breast cancer, higher SYTL4 levels tracked with longer survival. Levels were also higher in patients who responded to the drug trastuzumab. Chemical marks on the gene differed between tumor and healthy tissue. The author argues SYTL4 may flag both outlook and likely drug response, a claim that needs tests in patients.
Catalog record
| CREATOR | Pawel Kordowitzki |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |